Skip to content

EndoCard

Active Private limited companyfounded 2018active for 8 yearsNieuwenhovedreef 26, 8490 JabbekeKBO/BCE: BE 0697.720.802

Lifetime

8 annual accounts with figures on one time axis
peak of €998,754 in 2026
€998,754▲ 6.7%
peak of €650,049 in 2026
€650,049▲ 5.6%
peak of €821,037 in 2021
€669,936▲ 5.7%
€1.7m▲ 1.2%
Board3 names since 2018
2 directors and 1 other
Documentsfilings and deeds
23-10-20268 days before the deadline
2026micro format
Dividend €614,000Cash from €536,829 to €328,463

Key points

from the 2026 annual accounts

Equity

€669,936 ▲ 5.7%
633,8872025+650,049Profit-614,000Dividend669,9362026

EndoCard paid out €614,000 in dividends. That is 94% of the 2026 profit.

Debts

€1.7m 72% of the balance sheet
Financial debts 61%Suppliers 0%Taxes and wages 1%Other 38%

Of this, €644,059 falls due within a year.

Filings

8 annual accounts since 2019
deadline20202025

The last five annual accounts were filed 1 to 8 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,684 companies had the same profile as EndoCard has now. Each dot stands for 7 companies, two years later.

97.2%
were still trading
1.3%
stopped another way
1.3%
went bankrupt
  • Small
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,684 companies, not a prediction for EndoCard. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 05-06-2018
Manager, since 05-06-2018
  • arts aandeelhouderdeed of 31-12-2021
  • arts aandeelhouderdeed of 31-12-2021
Board & ownership

Recent changes

(director) and (director) reappointed General meeting of 04-06-2024 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0697720802
Company renamed from Dr. Nick Hiltrop-Dr. to EndoCard “De uitoefening van de geneeskunde door de artsen-aandeelhouders,meer bepaald van de geneeskunde met…” (deed in Dutch) · Partner: (arts aandeelhouder) · Partner: (arts aandeelhouder) · General meeting of 21-12-2021 · Gazette deed
Incorporation Founding capital of €18,600, 100 shares · Founded by ; · (manager) and (manager) appointed · published on 11-06-2018 · Gazette deed
All 16 events

Official details

Source: KBO
Status
Active since 07-06-2018Normal situation
Activity
“De uitoefening van de geneeskunde door de artsen-aandeelhouders,meer bepaald van de geneeskunde met specialisatie…” (deed in Dutch)From the articles, 2 activities1 activities on the establishment units
Establishment units
2.276.910.4948310 Bruges, since 07-06-2018
2.276.910.5938500 Kortrijk, since 07-06-2018
Financial year end
31 March
Peppol
Reachable since 24-11-2024
Company details

Annual accounts to 31-03-2026

≈ €2.0mestimated
€2.4m▲ 2.5%
Filing
Filed on 23-10-2026, 8 days before the end of the filing period
Financials

Insights on EndoCard

EndoCard files the micro format. That format states no turnover. The gross margin rose from €398,373 in 2019 to €998,754 in 2026.

The balance sheet grew most from 2023 to 2025 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about EndoCard

What is the company number of EndoCard?
The company number of EndoCard is 0697.720.802. The VAT number is the same number with BE in front: BE 0697.720.802.
Where is EndoCard based?
The registered office is at Nieuwenhovedreef 26, 8490 Jabbeke.Company details
What is the legal form of EndoCard?
EndoCard is a private limited company (BV).
When was EndoCard founded?
EndoCard was founded on 07-06-2018.
Is EndoCard still active?
Yes, EndoCard is an active enterprise in the KBO register.
What is the turnover of EndoCard?
The turnover in financial year 2026 is ≈ €2.0m. This figure is estimated from the gross margin of €998,754 and 1,019 comparable companies of the same size. It probably lies between €1.4m and €2.9m. It is a rough estimate.Financials
Is EndoCard profitable?
In financial year 2026, EndoCard made a profit of €650,049.
Where can I find the annual accounts of EndoCard?
EndoCard filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of EndoCard due?
EndoCard must file the annual accounts for financial year 2027 by 31-10-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.